Related references
Note: Only part of the references are listed.Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
B. Hanfstein et al.
LEUKEMIA (2014)
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
Francis J. Giles et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia
Claire M. Lucas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A Novel FRET-Based Biosensor for the Measurement of BCR-ABL Activity and Its Response to Drugs in Living Cells
Tatsuaki Mizutani et al.
CLINICAL CANCER RESEARCH (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
Jamshid Sorouri Khorashad et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
Dong Hwan Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
Silvia De Francia et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
Feng R. Luo et al.
CLINICAL CANCER RESEARCH (2006)
BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry
A. Hamilton et al.
LEUKEMIA (2006)
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
D White et al.
BLOOD (2005)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
